Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1683184 | 0.79 | IDO1 (0.60) | SMN1; SMN2TAAR1ALDH1A1KMT2AKDM4E | |
| SCHEMBL97308 | 0.78 | ALDH1A1 (0.35) | ALDH1A1IDO1 | |
| SCHEMBL98917 | 0.77 | IDO1 (0.55) | SMN1; SMN2TAAR1HPGDL3MBTL1IDO1 | |
| SCHEMBL2088676 | 0.74 | SLC22A12 (0.38) | SMN1; SMN2TAAR1ALDH1A1 | |
| SCHEMBL5537730 | 0.74 | MMP1 (0.40) | SMN1; SMN2TAAR1ALDH1A1KMT2AKDM4E | |
| SCHEMBL865249 | 0.74 | SMN1; SMN2 (0.52) | SMN1; SMN2AKR1B1TAAR1ALDH1A1KMT2A | |
| SCHEMBL2096467 | 0.71 | CA1 (0.41) | SMN1; SMN2ALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL9165701 | 0.70 | TAAR1 (0.50) | SMN1; SMN2AKR1B1TAAR1ALDH1A1KMT2A | |
| SCHEMBL19055351 | 0.70 | SMN1; SMN2 (0.48) | SMN1; SMN2AKR1B1TAAR1ALDH1A1KMT2A | |
| SCHEMBL13108637 | 0.70 | SMN1; SMN2 (0.48) | SMN1; SMN2AKR1B1TAAR1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 304 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822146-B2 | Process for the manufacture of degarelix and its intermediates | FERRING B.V. (NL) | 2017-11-21 | — | — | US | claimed |
| US-20160145301-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | FERRING BV (NL) | 2016-05-26 | — | — | US | claimed |
| EP-1177168-A4 | CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA INC (US) | 2003-06-25 | — | — | EP | claimed |
| JP-2002541237-A | — | — | 2002-12-03 | — | — | JP | claimed |
| EP-1189606-A2 | NOVEL IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING IRON CHELATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | YEDA RESEARCH AND DEVELOPMENT Co. LTD. (IL) | 2002-03-27 | — | — | EP | claimed |
| EP-1177168-A1 | CASPASE INHIBITORS AND THE USE THEREOF | Cytovia, Inc. (US) | 2002-02-06 | — | — | EP | claimed |
| WO-2000074664-A2 | NOVEL IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING IRON CHELATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2000-12-14 | — | — | WO | claimed |
| WO-2000061542-A1 | CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2000-10-19 | — | — | WO | claimed |
| US-4098777-A | OLIGOPEPTIDES, TREATMENT OF AUTOIMMUNE DISEASES | MERCK & CO., INC. (US) | 1978-07-04 | — | — | US | claimed |
| EP-3649146-B1 | APELIN PEPTIDES AND USES THEREOF | UNIV ALBERTA (CA) | 2024-06-26 | — | — | EP | disclosed |
| US-11186614-B2 | Anti-HIV peptides | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210115087-A1 | CYCLIC PEPTIDE INHIBITORS OF HEDGEHOG PROTEINS | UNIV ROCHESTER (US) | 2021-04-22 | — | — | US | disclosed |
| US-20200239537-A1 | APELIN PEPTIDES AND USES THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2020-07-30 | — | — | US | disclosed |
| US-10723776-B1 | Apelin peptides and uses thereof | THE GOVERNERS OF THE UNIVERSITY OF ALBERTA (CA) | 2020-07-28 | — | — | US | disclosed |
| US-4093574-A | Somatostatin analogs and intermediates thereto | ELI LILLY AND COMPANY (US) | 1978-06-06 | — | — | US | disclosed |
| US-4087390-A | Somatostatin analogs and intermediates thereto | ELI LILLY AND COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
| US-4076659-A | L-Val10 -somatostatin and intermediates thereto | ELI LILLY AND COMPANY (US) | 1978-02-28 | — | — | US | disclosed |
| US-4062816-A | D-Ala5 -somatostatin and intermediates thereto | ELI LILLY AND COMPANY (US) | 1977-12-13 | — | — | US | disclosed |
| US-4061626-A | GROWTH HORMONE STIMULANTS | ELI LILLY AND COMPANY (US) | 1977-12-06 | — | — | US | disclosed |
| US-4061607-A | Somatostatin analogs and intermediates thereto | ELI LILLY AND COMPANY (US) | 1977-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115087-A1 | CYCLIC PEPTIDE INHIBITORS OF HEDGEHOG PROTEINS | SHH, SMO, DACH1 | SMN1; SMN2 4579/4885AKR1B1 4703/4885TAAR1 2881/4885 |
| US-20160145301-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | VIP, HABP2, DPP9 | SMN1; SMN2 2834/4885AKR1B1 2302/4885TAAR1 3958/4885 |
| US-10723776-B1 | Apelin peptides and uses thereof | APLNR, MME, ANPEP | SMN1; SMN2 1266/4885AKR1B1 1008/4885TAAR1 3414/4885 |
| US-20200239537-A1 | APELIN PEPTIDES AND USES THEREOF | APLNR, MME, ANPEP | SMN1; SMN2 1266/4885AKR1B1 1008/4885TAAR1 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.